Interestingly, several recent reports demonstrate that antagonistic targeting of M-CSF can have appreciable benefit in tumor therapy as a consequence of altering the tumor-associated macrophage phenotype from M2 to M1 (49, 57–59). The gene discussed is CSF1; the disease is neoplasm.